Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
3.600
+0.150 (4.35%)
At close: Jun 10, 2025, 4:00 PM
3.780
+0.180 (5.00%)
After-hours: Jun 10, 2025, 5:57 PM EDT
Kyverna Therapeutics Employees
Kyverna Therapeutics had 112 employees as of December 31, 2024. The number of employees increased by 16 or 16.67% compared to the previous year.
Employees
112
Change (1Y)
16
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,298,384
Market Cap
155.59M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 112 | 16 | 16.67% |
| Dec 31, 2023 | 96 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
KYTX News
- 13 days ago - Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference - PRNewsWire
- 14 days ago - With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga
- 4 weeks ago - Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 2 months ago - Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 - Seeking Alpha
- 3 months ago - Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference - PRNewsWire
- 4 months ago - KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - PRNewsWire
- 4 months ago - Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX - GlobeNewsWire